Baylor University

CARGO Therapeutics Announces Appointment of Ginna Laport, MD, as Chief Medical Officer

Retrieved on: 
Tuesday, October 17, 2023
University, Stanford Cancer Institute, Antibody, Monoclonal antibody, Division, Drug, Research, Trial of the century, Stanford University School of Medicine, MD, Mosunetuzumab, BLA, IND, Health, Biotechnology, Medicine, Disease, Cancer, Patient, BA, Therapy, B-cell lymphoma, CAR, NME, CD22, Publication, SAN, CD19, BMT, Acceleration, Baylor University, B Division (New York City Subway), NIH, Pharmaceutical industry, Nursing, Stanford University, Blood

SAN MATEO, Calif., Oct. 17, 2023 (GLOBE NEWSWIRE) -- CARGO Therapeutics, Inc. (CARGO), a clinical-stage biotechnology company uniquely positioned to advance next generation, potentially curative cell therapies for cancer patients, today announced the appointment of Ginna Laport, MD, as Chief Medical Officer. Dr. Laport is a seasoned biotechnology executive and senior clinical leader. She will serve on the Company’s executive team and will be responsible for providing leadership and direction to guide CARGO’s clinical development strategy and execution, including the advancement of CARGO’s lead candidate, CRG-022, as well as its pipeline of next-generation CAR T-cell therapies for cancer patients. CRG-022 is an autologous CD22 chimeric antigen receptor (CAR) T-cell therapy candidate, currently in a potentially pivotal Phase 2 clinical trial in patients with large B-cell lymphoma (LBCL) whose disease relapsed or was refractory (R/R) to CD19 CAR T-cell therapy.

Key Points: 
  • SAN MATEO, Calif., Oct. 17, 2023 (GLOBE NEWSWIRE) -- CARGO Therapeutics, Inc. (CARGO), a clinical-stage biotechnology company uniquely positioned to advance next generation, potentially curative cell therapies for cancer patients, today announced the appointment of Ginna Laport, MD, as Chief Medical Officer.
  • “We are thrilled to announce the addition of Ginna to our team as Chief Medical Officer.
  • With her extensive leadership background in clinical drug development, particularly in hematology/oncology, she brings invaluable expertise to our organization,” said Gina Chapman, CARGO’s President and Chief Executive Officer.
  • Previously, Dr. Laport was Chief Medical Officer at Tempest Therapeutics, where she directed the clinical development of small molecules that combine both tumor-targeted and immune-mediated mechanisms, including several IND submissions.

Diakonos Oncology Awarded FDA Fast Track Designation for Innovative Dendritic Cell Vaccine for Glioblastoma

Retrieved on: 
Tuesday, October 17, 2023
Research, FDA, Clinical Trials, Stem Cells, Biotechnology, General Health, Pharmaceutical, Health, Science, Oncology, Incidence, Cancer, Fast track (FDA), Food, GBM, Glioblastoma, Standard of care, Cell, Central nervous system, University, University of Arizona College of Medicine – Tucson, B cell, Baylor College of Medicine, Survival, Disease, South Texas Medical Center, MD Anderson Cancer Center, Cooper University Hospital, Viral, Neurosurgery, Immunology, Person, Texas Medical Center, Clinical trial, Immune system, Fast Track, Associate, Assistant, Regulation of food and dietary supplements by the U.S. Food and Drug Administration, Injection, Baylor University, University of Arizona College of Medicine – Phoenix, Patient, Pharmaceutical industry, Vaccine

Diakonos Oncology Corporation (“Diakonos”), a clinical stage immuno-oncology company, announced today that the U.S. Food and Drug Administration (FDA) has granted Fast Track designation for the Company’s unique dendritic cell vaccine, DOC1021.

Key Points: 
  • Diakonos Oncology Corporation (“Diakonos”), a clinical stage immuno-oncology company, announced today that the U.S. Food and Drug Administration (FDA) has granted Fast Track designation for the Company’s unique dendritic cell vaccine, DOC1021.
  • The designation was based on positive preliminary safety and efficacy data from a Phase 1 clinical trial enrolling patients with glioblastoma multiforme (GBM).
  • FDA Fast Track designation is intended to speed development and review of drugs that show early clinical promise in treating severe or life-threatening conditions.
  • This pivotal designation can help propel Diakonos closer to delivering DOC1021 to GBM patients, of which only 7% survive more than five years.

The AIM-HI Accelerator Fund Recognizes, Honors, and Congratulates Its 2023 Women’s Venture Competition Top Winners

Retrieved on: 
Monday, October 16, 2023
Research, Women, Clinical Trials, Biotechnology, Health, Consumer, Other Science, Science, Oncology, T-cell acute lymphoblastic leukemia, MBA, TCL, Hope, Press club, T-ALL, RNA, United Nations Foundation, Distinction, Prize, National Foundation for Cancer Research, Baylor College of Medicine, CTC, Cancer, Winners, Therapy, MGD, Environment, Survivor, First Prize, Woman, Baylor University, Patient, National Press Club (United States), T-cell lymphoma, Pharmaceutical industry, Vaccine

Blue-ribbon judge committee members selected them from a pool of 71 female-led, early-stage oncology companies across 15 countries.

Key Points: 
  • Blue-ribbon judge committee members selected them from a pool of 71 female-led, early-stage oncology companies across 15 countries.
  • The Phase 1 clinical trial has demonstrated strong efficacy and safety signals, with multiple long-term survivors in remission years after treatment.
  • This recognition from AIM-HI is an acknowledgment of our hard work and an affirmation of our technology platform,” said Dr. Hein.
  • In addition to the first and second-place winners, Delee was selected as The 2023 People’s Choice for “Best Pitch” by a public audience voting for their favorite pitch presentation during the 2023 Women’s Venture Competition selection process.

SOUTHWEST AIRLINES ANNOUNCES LEADERSHIP PROMOTIONS

Retrieved on: 
Monday, October 16, 2023
Aircraft, Partnership, Senior, Oklahoma State University–Stillwater, Jordan, NYSE, University, Income Tax Department, Schedule, Fleet management, Moses Austin, Customer support, Union Pacific Railroad, Vesta C. Muehleisen, Engagement, Southwest Airlines, Finance, Amadeus, Wilson v Southwest Airlines Co, Corporation for Education Network Initiatives in California, Education, Culture, Boeing, Travel, FAA, Analysis, Flight dispatcher, Aviation, NOC, Compensation, Baylor University, Retirement, Airline, Management, Safety

DALLAS, Oct. 16, 2023 /PRNewswire/ -- Southwest Airlines Co. (NYSE: LUV) today announced recent Leadership updates across the Company.

Key Points: 
  • DALLAS, Oct. 16, 2023 /PRNewswire/ -- Southwest Airlines Co. (NYSE: LUV) today announced recent Leadership updates across the Company.
  • Prior to Southwest, Stephens held various positions in leadership and operations with Union Pacific Railroad.
  • "Strong Leadership is built upon serving, and Southwest Airlines boasts a longstanding tradition of remarkable Leaders who consistently prioritize the needs of our Employees and Customers over their own," said Bob Jordan , President & CEO at Southwest Airlines.
  • "I extend my sincere appreciation to Matt Hafner for his 35 years of service at Southwest Airlines.

Promontory Therapeutics Presents Data on the Molecular Effects of PT-112 at the AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics

Retrieved on: 
Saturday, October 14, 2023
European Organisation for Research and Treatment of Cancer, Treatment, Research and development, RNA, AACR, International Conference on Defects in Semiconductors, Baylor College of Medicine, EORTC, National Cancer Institute, Non-small-cell lung cancer, American Association for Cancer Research, Therapy, NCI, Gene, Prostate cancer, Prostate, Small RNA, Baylor University, Promontory, Conference, ICD, Pharmaceutical industry, Platinum, Vaccine, Doctor of Philosophy, Cancer, Research

NEW YORK, Oct. 14, 2023 /PRNewswire/ -- Promontory Therapeutics Inc., a clinical stage biotech company advancing immunogenic small molecule approaches in oncology, today presented data on its lead therapeutic candidate PT-112, detailing its early molecular effects that culminate in immunogenic cancer cell death (ICD). The presentation was made at the American Association for Cancer Research (AACR) – National Cancer Institute (NCI) – European Organisation for Research and Treatment of Cancer (EORTC) International Conference on Molecular Targets and Cancer Therapeutics, taking place October 11-15, 2023 in Boston.

Key Points: 
  • The presentation was made at the American Association for Cancer Research (AACR) – National Cancer Institute (NCI) – European Organisation for Research and Treatment of Cancer (EORTC) International Conference on Molecular Targets and Cancer Therapeutics, taking place October 11-15, 2023 in Boston.
  • Researchers also conducted nascent RNA sequencing in human cancer cells (non-small cell lung, prostate and renal cell carcinoma) following one and six hours of PT-112 treatment.
  • "While further validation of these findings is ongoing, this work deepens our understanding of PT-112's specific molecular effects.
  • PT-112 rapidly causes ribosomal biogenesis (RiBi) inhibition and nucleolar stress, likely driving previously observed PT-112-induced cancer organelle stresses and ICD.

MedReview Appoints Sean Diehl as New Vice President of Account Management and Customer Service

Retrieved on: 
Wednesday, October 11, 2023
Health management system, University, State, Customer service, Diehl, University of Idaho, Baylor University, State government, Management

NEW YORK, Oct. 11, 2023 /PRNewswire-PRWeb/ -- MedReview, Inc., a leading provider of payment integrity, utilization management, and quality surveillance services, is pleased to announce the appointment of Sean Diehl as Vice President of Account Management and Customer Service. Diehl brings two decades of experience in healthcare revenue operations and strategic partnerships and will report to MedReview's Chief Operating Officer, Kevin McDonald.

Key Points: 
  • MedReview, Inc., a leading provider of payment integrity, utilization management, and quality surveillance services, is pleased to announce the appointment of Sean Diehl as Vice President of Account Management and Customer Service.
  • NEW YORK, Oct. 11, 2023 /PRNewswire-PRWeb/ -- MedReview, Inc., a leading provider of payment integrity, utilization management, and quality surveillance services, is pleased to announce the appointment of Sean Diehl as Vice President of Account Management and Customer Service.
  • Diehl brings two decades of experience in healthcare revenue operations and strategic partnerships and will report to MedReview's Chief Operating Officer, Kevin McDonald.
  • Before joining MedReview, Diehl served as Vice President of Client Delivery at Conifer Health Solutions, where he provided client executive and strategy leadership for revenue cycle management and product sales to large health systems.

CurePSP Recognizes Three Prominent Medical Institutions for Their Care for PSP, CBD and MSA

Retrieved on: 
Thursday, October 5, 2023
Diagnosis, Dysautonomia, Social, Research, Corticobasal degeneration, Rush Alzheimer's Disease Center, Patient Centered Primary Care Collaborative, Neurology, MSA, Safety, University, Baylor College of Medicine, Palsy, PSP, Education, Vanderbilt University, Movement disorder, Nursing, LCSW, Growth, Deficit spending, DSM-IV codes, CBD, Roy, Multiple system atrophy, Baylor University, Patient, Parkinson's disease, Parkinson, Pharmaceutical industry, MSW

PSP, CBD and MSA, which are considered "atypical parkinsonian syndromes," often go underrecognized and underdiagnosed.

Key Points: 
  • PSP, CBD and MSA, which are considered "atypical parkinsonian syndromes," often go underrecognized and underdiagnosed.
  • Additionally, autonomic dysfunction (e.g., blood pressure regulation, urinary control) is a hallmark feature of MSA, while PSP and CBD can present with cognitive impairment and difficulty expressing words.
  • "The continued growth of our care network is one impactful way we can work toward improving the standard of care for PSP, CBD and MSA."
  • "Through becoming a CurePSP Center of Care, our ability to care for our patients will only expand and strengthen," Dr. Brown said.

Incorporating the Patient's Voice in NASH Clinical Trials, Upcoming Webinar Hosted by Xtalks

Retrieved on: 
Tuesday, October 3, 2023
PPD, KOL, Obesity, NASH, Baylor College of Medicine, Head, Baylor University, Human, Thermo Fisher Scientific, DSM-IV codes, Hepatology, Patient, Surgery, Fatty liver disease, Alcoholic hepatitis, Disease, Pharmaceutical industry, Medicine

TORONTO, Oct. 3, 2023 /PRNewswire-PRWeb/ -- There is immense interest in finding new therapies for non-alcoholic steatohepatitis (NASH), which is increasingly being known as metabolic-associated steatohepatitis (MASH), due to the unmet need and race to the market to get the first treatment approved. In parallel, the rates of MASH are increasing, and it is linked to the global obesity epidemic and related metabolic disorders. MASH is now expected to be the leading indication for liver transplant in the next few years, surpassing hepatitis C and Alcoholic Hepatitis. Despite the high rates of MASH, recruitment to clinical trials remains challenging in NASH clinical trials.

Key Points: 
  • Attendees will learn how to partner across the industry to improve the patient experience by using patient-centric trial strategies in NASH clinical trials.
  • The featured speakers will discuss the strategies to include the patient voice to aid in NASH patient recruitment and retention for clinical trials.
  • Despite the high rates of MASH, recruitment to clinical trials remains challenging in NASH clinical trials.
  • The panel will also discuss the way forward for building on the voice of patients to define strategies to improve patient recruitment and retention in NASH clinical trials.

TEXAS CHILDREN'S HOSPITAL CENTER FOR VACCINE DEVELOPMENT TEAM RECEIVES 2023 DAVID AND BEATRIX HAMBURG AWARD FOR VACCINE TECHNOLOGY DEVELOPMENT

Retrieved on: 
Thursday, September 28, 2023
Vaccine, Texas Children's Hospital, Partnership, Tropical medicine, COVID-19, Baylor University, Biomedical Research, Brooklyn Hospital Center, Infection, Biology, AAAS David and Betty Hamburg Award for Science Diplomacy, Bio Farma, National academy, National Academy of Medicine, IndoVac, National school, Baylor College of Medicine, Corbevax, Hospital, Health, Technology transfer, Disease, Pharmaceutical industry, Dentistry, DRS, Medicine

HOUSTON, Sept. 28, 2023 /PRNewswire/ -- Texas Children's Hospital is pleased to announce that the Texas Children's Hospital Center for Vaccine Development team has been awarded the 2023 David and Beatrix Hamburg Award for their development of a recombinant protein-based COVID-19 vaccine technology, created in Houston, which has benefited millions of people around the world.

Key Points: 
  • HOUSTON, Sept. 28, 2023 /PRNewswire/ -- Texas Children's Hospital is pleased to announce that the Texas Children's Hospital Center for Vaccine Development team has been awarded the 2023 David and Beatrix Hamburg Award for their development of a recombinant protein-based COVID-19 vaccine technology, created in Houston, which has benefited millions of people around the world.
  • "This recognition reinforces the importance of fostering exceptional, creative and interdisciplinary scientific teams to advance biomedical sciences that benefit humanity."
  • In India, the vaccine is produced under the name Corbevax by Biological E. Limited.
  • Botswana has also approved Corbevax and the Texas Children's team is further assisting with vaccine development capacity in Africa through a training program for scientists.

TEXAS TECH TO HOST THE UNIVERSITY OF HOUSTON IN BIG 12 HOME OPENER ON NEW HELLAS FIELD AT JONES AT&T STADIUM

Retrieved on: 
Thursday, September 28, 2023
NFL, University, AT&T Stadium, McLane Stadium, AT, 2023 Texas Tech Red Raiders football team, Jones AT&T Stadium and Cody Campbell Field, Baylor Bears, Attention, Texas Tech University, Baylor University, 2021 Baylor Bears football team, Texas Tech Red Raiders, The Red Raiders, Red Raiders, Dallas Cowboys, Management

LUBBOCK, Texas, Sept. 28, 2023 /PRNewswire/ -- Texas Tech University kicked off the 2023 college football season with a strong showing against nationally ranked Oregon at Jones AT&T Stadium.

Key Points: 
  • LUBBOCK, Texas, Sept. 28, 2023 /PRNewswire/ -- Texas Tech University kicked off the 2023 college football season with a strong showing against nationally ranked Oregon at Jones AT&T Stadium.
  • With non-conference games complete, attention now shifts to the Big 12 home opener against the University of Houston Cougars.
  • "The team loves the new field," says Texas Tech Head Football Coach Joey McGuire.
  • The Red Raiders and Cougars kick off at 2:30pm Saturday at Jones AT&T Stadium.